check quantity

IVISbrite MPO 425 Chemiluminescent Probe - RediJect Solution (4 vials) (XenoLight)

IVISbrite MPO 425 Chemiluminescent Probe in RediJect Solution ((XenoLight RediJect Inlammation Probe) is an in vivo imaging reagent for monitoring Inflammation. This probe is available in a ready-to-use format and can be conveniently applied to study myeloperoxidase (MPO) activity of activated phagocytes.

For research use only. Not for use in diagnostic procedures.

Part Number
Unit Size
List Price
Your Price
1 Kit (5 animals)
130.00 USD
1 Kit (20 animals)
326.00 USD
Buy Now

Please enter valid quantity

Please log in to add favorites.



The IVISbrite MPO 425 Chemiluminescent Probe in RediJect™ Solution enables longitudinal tracking of MPO level and inflammation status, in vivo, in a variety of disease models, including rheumatoid arthritis, acute septic shock, contact hypersensitivity reaction, and neutrophil rich cancers. This reagent comes in 4 vials, enough to inject 20 mice (based on 30g/mouse).

  • Novel ready-to-use probe to monitor phagocyte mediated inflammation non-invasively
  • Dispensed to image 20 animals (standard kit)
  • Includes a fluorescent tracer to validate substrate injection
  • Improved sensitivity due to the chemiluminescent read-out
  • In vivo imaging quality, validated on IVIS imaging systems


Optical Imaging Classification Chemiluminescence Imaging
Product Brand Name IVISbrite
Quantity in a Package Amount 20.0 Units
Shipping Condition Blue Ice
Therapeutic Area Arthritis, Inflammation
Unit Size 1 Kit (20 animals)
Resources, Events & More
  • All


XenoLight RediJect Inflammation Probe (Product Sheet)

XenoLight RediJect Inflammation Probe is a chemiluminescent reagent for monitoring inflammation. This probe is offered in a ready-to-use format and can be conveniently applied to study myeloperoxidase (MPO) activity of activated phagocytes. The RediJect Inflammation Probe will allow for longitudinal tracking of MPO level and inflammation status, in vivo, in a variety of disease models. This probe has been validated in vivo in detecting rheumatoid arthritis and contact hypersensitivity. Given the probe’s peak emission is 425 nm, the signal is significantly attenuated when imaging at depth, posing challenges for detecting inflammation in deep tissues.



In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.



IVISense™ Fluorescent Probe Selector Guide for Oncology Research

The goal of in vivo fluorescence molecular imaging is to enable non-invasive visualization and quantification of cellular and biological functioning to better understand and characterize disease processes and treatment effects earlier within the context of a biological system.

This selector guide for IVISense fluorescent probes is a powerful tool to help advance your oncology research. By matching probe properties to specific biology and biomarker characteristics, you can better understand how imaging and quantification of early biological changes associated with disease development, therapeutic efficacy, and drug-induced tissue changes can be realized.


White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 547 KB